Unpublished Study Ties Nolotil to Nine Deaths, Seven of Them British
A 2019 Valencia regional report found nine deaths from metamizole, sold as Nolotil, in Alicante. Seven were British. Spain's drug agency disputes it.

Nine people died in two years in coastal Alicante from a severe reaction to metamizole, the painkiller sold in Spain as Nolotil, and seven of them were British, according to an internal report by the Valencia regional government that was never published. EL PAÍS reported that it has obtained the 2019 document, whose findings were presented at the recent congress of the Spanish Society of Hospital Pharmacy (SEFH).
The report estimates that British patients ran a far higher risk of the reaction than Spaniards. Spain’s medicines regulator rejects that conclusion and says the study’s design cannot support it.
What the Alicante report counted
Nolotil is Spain’s best-selling branded drug and is regularly prescribed for pain and high fever, EL PAÍS said. Its best-known serious side effect is agranulocytosis, a sharp drop in granulocytes, a type of white blood cell. The condition can be fatal, particularly in elderly people and those with suppressed immune systems.
The study looked at severe reactions reported in 2016 and 2017 in the health areas of Denia, Villajoyosa, Torrevieja, San Juan and Orihuela. Those areas had 916,000 registered residents at the time, of whom 62,000 were originally from the United Kingdom and 28,000 from other northern European countries.
Researchers identified 41 patients hospitalized with agranulocytosis caused by metamizole. Of those, 26 were British and 11 Spanish, and the rest were one Danish, one Dutch, one Swedish and one Moroccan patient. Two of the nine people who died were Spanish.
To build the figures, the authors cross-checked hospital discharge records against outpatient use of the drug among people over 45, then read each medical record to confirm the patient had taken metamizole in the month before admission. Patients whose weakened immunity could have had another cause, such as an infection, another medication or cancer, were left out.
How much higher the risk looked for Britons
The report compared British and Spanish patients in two ways, according to EL PAÍS:
- By doses consumed, Spaniards had 0.33 cases per 100,000 defined daily doses and people from the United Kingdom had 39.8, a 120.7-fold higher risk.
- By patients treated, the rate among Spanish nationals was 0.084 cases per 1,000 (almost one in every 12,000) and among Britons 6.62 (one in every 151), a 78.8-fold higher risk.
Why Spain’s regulator disputes the findings
The Spanish Medication and Health Products Agency (AEMPS), the national drug regulator, told EL PAÍS in writing that the report has serious limitations because “it is not analytical but descriptive” and does not allow incidence or relative risk to be calculated. The agency’s position is that the available information neither confirms nor rules out a higher risk in populations with particular ethnic or genetic characteristics, and that the drug’s benefits still outweigh its risks.
AEMPS pointed to its own study, published in 2024 in the European Journal of Clinical Pharmacology. That paper found agranulocytosis was very rare but more than four times more common with metamizole than with other painkillers. It also said the small number of cases meant chance could not be excluded, and it did not separate patients by country of birth.
Vicente Palop, of the medication working group at the Spanish Society of Family and Community Medicine (semFYC), criticized the regulator’s handling of the drug. He told EL PAÍS there is “a serious problem of transparency and reporting” and that the true scale of adverse effects is unknown, among Spaniards as well as northern Europeans.
What it means for British and northern European residents in Spain
Metamizole is not sold in the United Kingdom, Ireland, France, Sweden, Denmark or the United States, which are among the countries that withdrew it because of agranulocytosis. Some 30 other countries have done the same. It remains widely used in Germany, where it was first marketed in 1922, and in Austria, Italy, Portugal, Russia and Turkey.
In 2018, after British news outlets reported that a dozen UK citizens had died after taking the drug in Spain, AEMPS recommended that it not be used for longer than one week and advised against it in transient populations. The study’s author, José Luis Marco Garbayo, said at an SEFH event that the recommendation was aimed at tourists when the risk lies with people from those countries who live in Spain.
Hospitals in areas with many foreign residents, including the Costa del Sol and Denia, have adopted their own measures to prevent such cases, EL PAÍS reported. Several lawsuits have followed, and most are still pending.
The European Medicines Agency reviewed the drug between 2023 and 2024 after Finland decided to withdraw it. The agency concluded that the benefits still outweighed the risks and called for changes to package leaflets so that complications are detected sooner.
Source: El País English
